ENSC - Ensysce Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ENSC

ENSYSCE BIOSCIENCES, INC.

NASDAQ

$0.40

▲ UP 0.23% (0.00)

KEY STATISTICS

Market Cap$6.14 M

52w High$2.75

52w Low$0.23

Dividend Yield—

Frequency—

P/E-0.14

Volume486.12K

Shares Out.15.37M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

D. Lynn Kirkpatrick

COMPENSATION 2026

Salary$432,042

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$10,350

Total$442,392

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 14, 2018

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.$1.20M

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2024-12-06	Reverse	1:15
2023-03-31	Reverse	1:12
2022-10-28	Reverse	1:20

PRICE

$0.40 ▲ UP 0.23% (+$0.00)

OVERLAYS

About Ensysce Biosciences, Inc.

https://www.ensysce.com ↗

Ensysce Biosciences is a clinical-stage biotech developing abuse-resistant and overdose-protective opioid prodrugs, including PF614 and PF26810, for pain management, addiction, and overdose prevention.

INDUSTRY

Biotechnology

A PRODUCT ENSYSCE BIOSCIENCES, INC. IS KNOWN FOR

PF614

PF614, a clinical-stage opioid from Ensysce's TAAP platform, is designed to treat severe pain with abuse prevention features and is currently in Phase 3 trials assessing its safety and efficacy.